[1] BUCCAFUSCA G, PROSERPIO I, TRALONGO A C, et al. Early colorectal cancer: diagnosis, treatment and survivorship care[J]. Crit Rev Oncol Hematol, 2019, 136: 20-30. DOI: 10.1016/j.critrevonc.2019.01.023. [2] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590. [3] ARNOLD M, SIERRA M S, LAVERSANNE M, et al. Global patterns and trends in colorectal cancer incidence and mortality[J]. Gut, 2017, 66(4): 683-691. DOI: 10.1136/gutjnl-2015-310912. [4] 舒密,南琼.间期大肠癌临床和分子学特征的研究进展[J].医学研究生学报, 2018, 31(9): 1005-1008. DOI: 10.16571/j.cnki.1008-8199.2018.09.022. [5] TOH J W T, PHAN K, REZA F, et al. Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis[J]. Int J Colorectal Dis, 2021, 36(8): 1573-1596. DOI: 10.1007/s00384-021-03874-1. [6] BENSON A B, VENOOK A P, AL-HAWARY M M, et al. NCCN guidelines insights: colon cancer, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(4): 359-369. DOI: 10.6004/jnccn.2018.0021. [7] LUCHINI C, BIBEAU F, LIGTENBERG M J L, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach[J]. Ann Oncol, 2019, 30(8): 1232-1243. DOI: 10.1093/annonc/mdz116. [8] ANJOMSHOAA A, NASRI S, HUMAR B, et al. Slow proliferation as a biological feature of colorectal cancer metastasis[J]. Br J Cancer, 2009, 101(5): 822-828. DOI: 10.1038/sj.bjc.6605229. [9] MAYERHOEFER M E, MATERKA A, LANGS G, et al. Introduction to radiomics[J]. J Nucl Med, 2020, 61(4): 488-495. DOI: 10.2967/jnumed.118.222893. [10] MEROK M A, AHLQUIST T, RØYRVIK E C, et al. Microsatellite instability has a positive prognostic impact on stage Ⅱ colorectal cancer after complete resection: results from a large, consecutive Norwegian series[J]. Ann Oncol, 2013, 24(5): 1274-1282. DOI: 10.1093/annonc/mds614. [11] YING M L, PAN J F, LU G H, et al. Development and validation of a radiomics-based nomogram for the preoperative prediction of microsatellite instability in colorectal cancer[J]. BMC Cancer, 2022, 22(1): 524. DOI: 10.1186/s12885-022-09584-3. [12] CAO W, HU H, GUO J, et al. CT-based deep learning model for the prediction of DNA mismatch repair deficient colorectal cancer: a diagnostic study[J]. J Transl Med, 2023, 21(1): 214. DOI: 10.1186/s12967-023-04023-8. [13] WANG Q, XU J, WANG A, et al. Systematic review of machine learning-based radiomics approach for predicting microsatellite instability status in colorectal cancer[J]. Radiol Med, 2023, 128(2): 136-148. DOI: 10.1007/s11547-023-01593-x. [14] GOLIA PERNICKA J S, GAGNIERE J, CHAKRABORTY J, et al. Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation[J]. Abdom Radiol(NY), 2019, 44(11): 3755-3763. DOI: 10.1007/s00261-019-02117-w. [15] FAN S X, LI X B, CUI X N, et al. Computed tomography-based radiomic features could potentially predict microsatellite instability status in stage Ⅱ colorectal cancer: a preliminary study[J]. Acad Radiol, 2019, 26(12): 1633-1640. DOI: 10.1016/j.acra.2019.02.009. [16] WU J J, ZHANG Q H, ZHAO Y, et al. Radiomics analysis of iodine-based material decomposition images with dual-energy computed tomography imaging for preoperatively predicting microsatellite instability status in colorectal cancer[J]. Front Oncol, 2019, 9: 1250. DOI: 10.3389/fonc.2019.01250. [17] WANG X H, LIU Z Q, YIN X P, et al. A radiomics model fusing clinical features to predict microsatellite status preoperatively in colorectal cancer liver metastasis[J]. BMC Gastroenterol, 2023, 23(1): 308. DOI: 10.1186/s12876-023-02922-0. [18] 陈渝宏,杨彪,廖正银.免疫治疗相关生物标志物在消化道肿瘤中的应用[J].中国肿瘤临床, 2022, 49(12): 631-635. DOI: 10.12354/j.issn.1000-8179.2022.20211501. [19] PRICE T J, BEEKE C, ULLAH S, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? [J]. Cancer, 2015, 121(6): 830-835. DOI: 10.1002/cncr.29129. [20] LOUPAKIS F, YANG D Y, YAU L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer[J]. J Natl Cancer Inst, 2015, 107(3): dju427. DOI: 10.1093/jnci/dju427. [21] ZAANAN A, SHI Q, TAIEB J, et al. Role of deficient DNA mismatch repair status in patients with stage Ⅲ colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials[J]. JAMA Oncol, 2018, 4(3): 379-383. DOI: 10.1001/jamaoncol.2017.2899. [22] RIBIC C M, SARGENT D J, MOORE M J, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer[J]. N Engl J Med, 2003, 349(3): 247-257. DOI: 10.1056/NEJMoa022289. [23] SHULMAN K, BARNETT-GRINESS O, FRIEDMAN V, et al. Outcomes of chemotherapy for microsatellite instable-high metastatic colorectal cancers[J]. JCO Precis Oncol, 2018, 2: PO.17.00253. DOI: 10.1200/PO.17.00253. [24] SARGENT D J, MARSONI S, MONGES G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol, 2010, 28(20): 3219-3226. DOI: 10.1200/JCO.2009.27.1825. |